MYBPC3-associated cardiomyopathy: features of the course and prospects for specific therapy
Open Access
- 13 February 2025
- journal article
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 23 (12) , 4257
Abstract
Genetic cardiomyopathies (CMP) are a group of diseases characterized by myocardial pathology not caused by hypertension, coronary artery disease, congenital and acquired defects. Development of imaging methods and molecular genetic diagnostics showed that the traditional phenotypic classification does not fully meet modern needs due to the presence of clinical, morphological and genotypic "crossing" of CMP. At the same time, in recent years, data have been obtained showing that the genetic substrate has a significantly higher prognostic value compared to the phenotype and plays a significant role in risk stratification and the choice of patient management tactics, as well as in family screening. Taken together, this has led to a shift in focus from phenotypic features to genotype as the basis for modern classifications of cardiomyopathy. One example of such a genotype-specific approach is the identification of cardiomyopathy associated with MYBPC3 gene variants as an independent entity. The aim of the article was to describe the role of MYBPC3 gene and the cardiac myosin-binding protein C encoded by it in cardiomyocyte function, to present current literature data on pathogenesis, clinical features and developing strategies for MYBPC3cardiomyopathy treatment, as well as to highlight current problems and directions for future research in this area.Keywords
This publication has 46 references indexed in Scilit:
- 2024 AHA/ACC/AMSSM/HRS/PACES/SCMR Guideline for the Management of Hypertrophic CardiomyopathyJACC, 2024
- Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4Journal of Cardiac Failure, 2024
- Mavacamten in Patients With Hypertrophic Cardiomyopathy Referred for Septal ReductionJAMA Cardiology, 2023
- Accurate Classification of Non-ischemic CardiomyopathyCurrent Cardiology Reports, 2023
- Circulating Acylcarnitines Associated with Hypertrophic Cardiomyopathy Severity: an Exploratory Cross-Sectional Study in MYBPC3 Founder Variant CarriersJournal of Cardiovascular Translational Research, 2023
- Prognostic Prediction of Genotype vs Phenotype in Genetic CardiomyopathiesJACC, 2022
- Diagnosis and Evaluation of Hypertrophic CardiomyopathyJACC, 2022
- Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathyForensic Science International: Genetics, 2021
- Clinical and ECG variables to predict the outcome of genetic testing in hypertrophic cardiomyopathyEuropean Journal of Medical Genetics, 2020
- Allelic imbalance and haploinsufficiency in MYBPC3-linked hypertrophic cardiomyopathyPflügers Archiv - European Journal of Physiology, 2018